Diagnostics News and Research

RSS

Forbion Capital Partners announces final closing of FCF I, FCF II fund

Forbion Capital Partners, a leading investment firm dedicated to the life science sector, today announces the final closings of both FCF I Co-Invest Fund and of FCF II, raising a total of more than €190m ($240m). Forbion's €54m Co-Invest Fund aims to invest alongside FCF I in a select number of late-stage FCF I portfolio companies.

3 Sep 2010

NEJM publishes study on Xpert MTB/RIF test for rapid molecular detection of TB and rifampin resistance

Cepheid today announced that its Xpert® MTB/RIF test was the subject of a study published in the latest edition of the New England Journal of Medicine (NEJM), "Rapid Molecular Detection of Tuberculosis and Rifampin Resistance." The complete study is now available online (http://www.nejm.org) and will appear in the September 9 print edition.

3 Sep 2010

New TB diagnostic test effective in first large-scale field trial

Research assessing the effectiveness of a new diagnostic test for the detection of tuberculosis (TB) is featured in the Sept. 1 edition of the New England Journal of Medicine.

3 Sep 2010

New test detects TB faster, with more accuracy than current diagnostics, study says

A new molecular test for tuberculosis can diagnose the disease and detect a drug-resistant form of it in less than two hours and more accurately than current tests, according to the findings of a study published online in the New England Journal of Medicine on Wednesday, Reuters reports (Kelland, 9/1).

3 Sep 2010

Accumetrics secures $24 million in capital infusion

Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced today that it has completed its capital financing efforts, the first round of which was announced in the Fall of 2009.

2 Sep 2010

Asuragen launches KRAS, BRAF mutational testing in CLIA laboratory

Asuragen, Inc., a leader in molecular diagnostics and nucleic acid-based pharmacogenomics services, announced today that it has launched KRAS and BRAF mutational testing services in its CAP-accredited CLIA laboratory.

2 Sep 2010

MIRACLE project to develop lab-on-chip system for diagnosing cancer

Today, at the Engineering in Medicine and Biology Conference in Buenos Aires (Argentina), imec and its project partners announce the launch of the European Seventh Framework Project MIRACLE. The MIRACLE project aims at developing an operational lab-on-chip for the isolation and detection of circulating and disseminated tumor cells in blood.

2 Sep 2010

Abbott RealTime HBV assay receives marketing approval from FDA

Abbott announced today it has received approval from the U.S. Food and Drug Administration to market the Abbott RealTime HBV assay for measuring viral load or the amount of hepatitis B virus in a patient's blood. It is the first and only approved test capable of automating HBV viral load testing from sample extraction to final results.

2 Sep 2010

Burrill conference to provide insights into challenges and opportunities in personalized medicine

"Healthcare is now shifting towards predictive and preventative care utilizing diagnostics that allow physicians to follow the course of a disease, evaluate which therapeutic regimes are most effective, and determine long-term susceptibility and recurrence," said G. Steven Burrill, CEO of Burrill & Company. "As diseases are better understood at a molecular level, the promise of personalized medicine is becoming a reality.

31 Aug 2010

Biotage launches new Resolux line of HPLC columns optimized for peptide purification

Biotage, a leading supplier of tools and technology for medicinal and analytical chemistry, has launched a new range of HPLC columns optimized for peptide purification. The Resolux™ line was introduced during the ACS Fall 2010 National Meeting & Exposition in Boston, Massachusetts USA and will be premiered at the 31st European Peptide Symposium on September 5th in Copenhagen, Denmark.

31 Aug 2010

MGH scientists develop new microfluidic tool for accurate isolation of neutrophils

A team led by Massachusetts General Hospital (MGH) scientists has developed a new microfluidic tool for quickly and accurately isolating neutrophils - the most abundant type of white blood cell - from small blood samples, an accomplishment that could provide information essential to better understanding the immune system's response to traumatic injury. The system, described in a Nature Medicine paper that received advance online release, also can be adapted to isolate almost any type of cell.

31 Aug 2010

NEC, SomaLogic sign agreement to explore aptamer related businesses in life sciences, healthcare markets

NEC Corporation and privately held SomaLogic, Inc. announced today that they have signed an agreement to explore aptamer related businesses in the life sciences and healthcare markets. In addition, NEC announced that it has made an equity investment in SomaLogic in support of a long-term strategic relationship between the two companies.

31 Aug 2010

RXR-alpha protein helps to protect pigment cells from invasive melanoma: Research

New research on how skin cancer begins has identified adjacent cancer cells that scientists are calling "co-conspirators" in the genesis of melanoma, in findings that could someday hold the key to predicting, preventing and stopping this hard-to-treat cancer before it spreads.

31 Aug 2010

MRI recordings at one fiftieth of a second

"Please hold absolutely still": This instruction is crucial for patients being examined by magnetic resonance imaging (MRI). It is the only way to obtain clear images for diagnosis. Up to now, it was therefore almost impossible to image moving organs using MRI. Max Planck researchers from G-ttingen have now succeeded in significantly reducing the time required for recording images - to just one fiftieth of a second.

30 Aug 2010

Biomagnetics to acquire Lanzhou New Sunshine Plastics Industry

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, and other innovative technologies, today announced the signing of a Letter of Intent (LOI) with Lanzhou New Sunshine Plastics Industry LTD. This expected acquisition is the fourth planned acquisition targeted at a share price of US $1.50 for Biomagnetics Diagnostics' common shares.

30 Aug 2010

Lineagen completes $10.8 million Series A financing

Lineagen, Inc., a developer of innovative genomic tests and services for the screening, evaluation and diagnosis of complex disorders and diseases including autism spectrum disorders and others, today announced that PrairieGold Venture Partners has joined Lineagen's existing institutional venture investors in a further $5 million closing of its Series A round, which completes Lineagen's $10.8 million Series A financing.

30 Aug 2010

Mobile Health Expo conference program highlights international nature of mobile health

Mobile Health Expo, the only event focusing on the convergence of mobile technology and healthcare across the entire mobile health ecosystem, today revealed some highlights from the conference program that focuses on the truly international nature of mobile health. Speakers representing both developing and developed nations will share case studies and best practices of how mobile health is being used in other countries.

30 Aug 2010

SQI Diagnostics 2010 third quarter net loss increases to $1,613K

SQI Diagnostics Inc.,a medical systems automation company focused on evolving laboratory-based biomarker testing, today announced its financial and operational results for the third quarter ended June 30, 2010.

30 Aug 2010

Biomagnetics Diagnostics to acquire Hubei Tianyuan Chemical

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, and other innovative technologies, today announced the signing of a Letter of Intent (LOI) with Hubei Tianyuan Chemical Co., Ltd. of Yangxin Nacheng Chemical Industry Zone, located in Hubei Province, China.

27 Aug 2010

'Molecular Diagnostics Europe' conference debuts at BIOTECHNICA 2010

BIOTECHNICA, Europe's Leading Exhibition for Biotechnology and Life Sciences, is broadening its portfolio to include a new conference and special display on molecular diagnostics. Produced by the Cambridge Healthtech Institute, a leading organizer of biomedical conferences in the United States, the "Molecular Diagnostics Europe" (MDxEU) conference is making its debut this year. The main focus will be on new methods for molecular diagnostics, particularly with regard to cancer and infectious diseases.

27 Aug 2010

Diagnostics News and Research

Forbion Capital Partners announces final closing of FCF I, FCF II fund

NEJM publishes study on Xpert MTB/RIF test for rapid molecular detection of TB and rifampin resistance

New TB diagnostic test effective in first large-scale field trial

New test detects TB faster, with more accuracy than current diagnostics, study says

Accumetrics secures $24 million in capital infusion

Asuragen launches KRAS, BRAF mutational testing in CLIA laboratory

MIRACLE project to develop lab-on-chip system for diagnosing cancer

Abbott RealTime HBV assay receives marketing approval from FDA

Burrill conference to provide insights into challenges and opportunities in personalized medicine

Biotage launches new Resolux line of HPLC columns optimized for peptide purification

MGH scientists develop new microfluidic tool for accurate isolation of neutrophils

NEC, SomaLogic sign agreement to explore aptamer related businesses in life sciences, healthcare markets

RXR-alpha protein helps to protect pigment cells from invasive melanoma: Research

MRI recordings at one fiftieth of a second

Biomagnetics to acquire Lanzhou New Sunshine Plastics Industry

Lineagen completes $10.8 million Series A financing

Mobile Health Expo conference program highlights international nature of mobile health

SQI Diagnostics 2010 third quarter net loss increases to $1,613K

Biomagnetics Diagnostics to acquire Hubei Tianyuan Chemical

'Molecular Diagnostics Europe' conference debuts at BIOTECHNICA 2010

Event guide: 16th Clinical Biomarkers & CDx Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News